Robert W. Baird reaffirmed their buy rating on shares of Davita (NYSE:DVA) in a research note issued to investors on Friday, January 12th. Robert W. Baird currently has a $95.00 price objective on the stock, up from their prior price objective of $82.00.
A number of other research analysts also recently issued reports on the stock. Wolfe Research upgraded shares of Davita from a market perform rating to an outperform rating in a research report on Monday, October 23rd. Bank of America dropped their price target on shares of Davita from $75.00 to $66.00 and set a neutral rating on the stock in a research report on Wednesday, November 8th. JPMorgan Chase & Co. downgraded shares of Davita from a neutral rating to an underweight rating in a research report on Monday, October 9th. Zacks Investment Research downgraded shares of Davita from a hold rating to a sell rating in a research report on Wednesday, October 11th. Finally, Raymond James Financial upgraded shares of Davita from an outperform rating to a strong-buy rating and boosted their price target for the stock from $65.00 to $84.00 in a research report on Thursday, December 7th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $78.22.
Shares of Davita (NYSE DVA) opened at $78.19 on Friday. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 1.79. Davita has a 1 year low of $52.51 and a 1 year high of $80.71. The company has a market cap of $14,330.00, a P/E ratio of 29.96 and a beta of 0.96.
Davita (NYSE:DVA) last posted its earnings results on Tuesday, November 7th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.13). The business had revenue of $3.92 billion for the quarter, compared to analyst estimates of $3.91 billion. Davita had a return on equity of 13.31% and a net margin of 3.40%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.95 earnings per share. analysts predict that Davita will post 3.42 earnings per share for the current year.
Davita declared that its board has initiated a share buyback plan on Tuesday, October 10th that authorizes the company to buyback $1.50 billion in outstanding shares. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.
In other Davita news, VP Leanne M. Zumwalt sold 949 shares of the business’s stock in a transaction on Friday, December 8th. The shares were sold at an average price of $68.19, for a total transaction of $64,712.31. Following the completion of the sale, the vice president now owns 12,423 shares in the company, valued at approximately $847,124.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James K. Hilger sold 3,572 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $78.95, for a total transaction of $282,009.40. Following the sale, the insider now owns 33,649 shares of the company’s stock, valued at approximately $2,656,588.55. The disclosure for this sale can be found here. Insiders have sold a total of 121,509 shares of company stock worth $8,310,388 in the last quarter. 2.10% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the business. Coastline Trust Co increased its stake in Davita by 6.3% during the 4th quarter. Coastline Trust Co now owns 16,120 shares of the company’s stock valued at $1,165,000 after purchasing an additional 950 shares in the last quarter. Creative Planning increased its stake in Davita by 8.6% during the 4th quarter. Creative Planning now owns 13,137 shares of the company’s stock valued at $949,000 after purchasing an additional 1,044 shares in the last quarter. Founders Capital Management LLC increased its stake in Davita by 2.3% during the 3rd quarter. Founders Capital Management LLC now owns 95,939 shares of the company’s stock valued at $5,698,000 after purchasing an additional 2,115 shares in the last quarter. CAPROCK Group Inc. increased its stake in Davita by 53.2% during the 4th quarter. CAPROCK Group Inc. now owns 6,290 shares of the company’s stock valued at $498,000 after purchasing an additional 2,183 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in Davita during the 3rd quarter valued at $154,000. Institutional investors and hedge funds own 87.97% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Davita’s (NYSE:DVA) Buy Rating Reaffirmed at Robert W. Baird” was reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.truebluetribune.com/2018/01/19/robert-w-baird-reaffirms-buy-rating-for-davita-dva.html.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.